熊去氧膽酸

熊去氧膽酸(英語:Ursodeoxycholic acid,也被稱為3α,7β-二羥基-5β-膽烷-24-羧酸,3α,7β-dihydroxy-5β-cholan-24-oic acid,縮寫 UDCA),是一種來自熊膽膽汁酸[1],為次級膽汁酸,由初級膽汁酸經由細菌代謝生成。

Ursodeoxycholic acid
臨床資料
商品名英語Drug nomenclatureActigall
其他名稱ursodeoxycholic acid, Actigall, Ursosan, Urso, Urso Forte
AHFS/Drugs.comMonograph
MedlinePlusa699047
核准狀況
懷孕分級
給藥途徑oral
ATC碼
法律規範狀態
法律規範
識別資訊
  • 3α,7β-dihydroxy-5β-cholan-24-oic acid
    OR
    (R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-
    10,13-dimethylhexadecahydro-
    1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
CAS號128-13-2  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB配體ID
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.004.437 編輯維基數據鏈接
化學資訊
化學式C24H40O4
摩爾質量392.56 g/mol
3D模型(JSmol英語JSmol
熔點203 °C(397 °F)
  • O=C(O)CC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]4[C@H]2[C@@H](O)C[C@@H]3C[C@H](O)CC[C@@]34C)C
  • InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1 checkY
  • Key:RUDATBOHQWOJDD-UZVSRGJWSA-N checkY

它可以降低細胞表面ACE2受體的表達量。[2]

歷史

熊膽是熊去氧膽酸的天然來源。1955年,日本科學家成功化學合成了熊去氧膽酸[3]。1987年12月,艾爾建申請的熊去氧膽酸獲准在美國上市。[4]

參考文獻

  1. ^ 放過熊吧!可治療膽結石的熊膽早就能用化學合成. 食力 foodNEXT. [2021-12-08]. (原始內容存檔於2021-12-08) (中文(臺灣)). 
  2. ^ Teresa Brevini, Mailis Maes, Gwilym J. Webb, Binu V. John, Claudia D. Fuchs, Gustav Buescher, Lu Wang, Chelsea Griffiths, Marnie L. Brown, William E. Scott, Pehuén Pereyra-Gerber, William T. H. Gelson, Stephanie Brown, Scott Dillon, Daniele Muraro, Jo Sharp, Megan Neary, Helen Box, Lee Tatham, James Stewart, Paul Curley, Henry Pertinez, Sally Forrest, Petra Mlcochova, Sagar S. Varankar, Mahnaz Darvish-Damavandi, Victoria L. Mulcahy, Rhoda E. Kuc, Thomas L. Williams, James A. Heslop, Davide Rossetti, Olivia C. Tysoe, Vasileios Galanakis, Marta Vila-Gonzalez, Thomas W. M. Crozier, Johannes Bargehr, Sanjay Sinha, Sara S. Upponi, Corrina Fear, Lisa Swift, Kourosh Saeb-Parsy, Susan E. Davies, Axel Wester, Hannes Hagström, Espen Melum, Darran Clements, Peter Humphreys, Jo Herriott, Edyta Kijak, Helen Cox, Chloe Bramwell, Anthony Valentijn, Christopher J. R. Illingworth, UK-PBC research consortium, Bassam Dahman, Dustin R. Bastaich, Raphaella D. Ferreira, Thomas Marjot, Eleanor Barnes, Andrew M. Moon, Alfred S. Barritt, Ravindra K. Gupta, Stephen Baker, Anthony P. Davenport, Gareth Corbett, Vassilis G. Gorgoulis, Simon J. A. Buczacki, Joo-Hyeon Lee, Nicholas J. Matheson, Michael Trauner, Andrew J. Fisher, Paul Gibbs, Andrew J. Butler, Christopher J. E. Watson, George F. Mells, Gordon Dougan, Andrew Owen, Ansgar W. Lohse, Ludovic Vallier, Fotios Sampaziotis. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022-12-05 [2022-12-07]. ISSN 0028-0836. doi:10.1038/s41586-022-05594-0. (原始內容存檔於2023-06-26) (英語). 
  3. ^ Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. Journal of Ethnobiology and Ethnomedicine. 2009, 5 (1): 2. PMC 2630947 . PMID 19138420. doi:10.1186/1746-4269-5-2. 
  4. ^ Actigall: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [29 April 2020]. (原始內容存檔於2020-10-19). 

外部連結